Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BTX 1303
- Development stage
- Preclinical
- Lead developer
- Botanix Pharmaceuticals
- Administration
- Topical
01
Overview
BTX 1303 is an investigational topical dermatology drug candidate developed by Botanix Pharmaceuticals for the treatment of psoriasis. It was advanced through preclinical development as part of Botanix’s BTX pipeline of synthetic cannabinoid-based or related dermatologic therapies, with the goal of providing a new mechanism of action and improved topical delivery for inflammatory skin disease; however, detailed public information on its exact active ingredient, molecular target, and formulation has not been disclosed.
Beyond the preview
Go deeper on BTX 1303.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BTX 1303.